INBXInhibrx Biosciences, IncRunning, no new patients
Study of INBRX-109 in Conventional Chondrosarcoma
Conventional Chondrosarcoma
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Sep 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 2
- Patients
- 206 (final count)
- Started
- Sep 23, 2021
- Main results expected
- Sep 30, 2025
- Fully finished
- Dec 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival per RECISTv1.1 by real time IRR comparing INBRX-109 and placebo
Measured over: 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-09-30, no fading
Raw record changes
- none yet
Trial ID NCT04950075 · record last updated 2026-07-14 · checked 2026-11-09 15:47 UTC